Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 762
Filtrer
1.
Surg Endosc ; 2024 Aug 13.
Article de Anglais | MEDLINE | ID: mdl-39138678

RÉSUMÉ

INTRODUCTION: Although several studies report that the robotic approach is more costly than laparoscopy, the cost-effectiveness of robotic distal pancreatectomy (RDP) over laparoscopic distal pancreatectomy (LDP) is still an issue. This study evaluates the cost-effectiveness of the RDP and LDP approaches across several Spanish centres. METHODS: This study is an observational, multicenter, national prospective study (ROBOCOSTES). For one year from 2022, all consecutive patients undergoing minimally invasive distal pancreatectomy were included, and clinical, QALY, and cost data were prospectively collected. The primary aim was to analyze the cost-effectiveness between RDP and LDP. RESULTS: During the study period, 80 procedures from 14 Spanish centres were analyzed. LDP had a shorter operative time than the RDP approach (192.2 min vs 241.3 min, p = 0.004). RDP showed a lower conversion rate (19.5% vs 2.5%, p = 0.006) and a lower splenectomy rate (60% vs 26.5%, p = 0.004). A statistically significant difference was reported for the Comprehensive Complication Index between the two study groups, favouring the robotic approach (12.7 vs 6.1, p = 0.022). RDP was associated with increased operative costs of 1600 euros (p < 0.031), while overall cost expenses resulted in being 1070.92 Euros higher than the LDP but without a statistically significant difference (p = 0.064). The mean QALYs at 90 days after surgery for RDP (0.9534) were higher than those of LDP (0.8882) (p = 0.030). At a willingness-to-pay threshold of 20,000 and 30,000 euros, there was a 62.64% and 71.30% probability that RDP was more cost-effective than LDP, respectively. CONCLUSIONS: The RDP procedure in the Spanish healthcare system appears more cost-effective than the LDP.

2.
Parkinsons Dis ; 2024: 5519396, 2024.
Article de Anglais | MEDLINE | ID: mdl-39104613

RÉSUMÉ

Parkinson's disease (PD) is a neurodegenerative disorder characterized by alterations in motor capacity resulting from a decrease in the neurotransmitter dopamine due to the selective death of dopaminergic neurons of the nigrostriatal pathway. Unfortunately, conventional pharmacological treatments fail to halt disease progression; therefore, new therapeutic strategies are needed, and currently, some are being investigated. The endocannabinoid system (ECS), highly expressed in the basal ganglia (BG) circuit, undergoes alterations in response to dopaminergic depletion, potentially contributing to motor symptoms and the etiopathogenesis of PD. Substantial evidence supports the neuroprotective role of the ECS through various mechanisms, including anti-inflammatory, antioxidative, and antiapoptotic effects. Therefore, the ECS emerges as a promising target for PD treatment. This review provides a comprehensive summary of current clinical and preclinical evidence concerning ECS alterations in PD, along with potential pharmacological targets that may exert the protection of dopaminergic neurons.

3.
Plants (Basel) ; 13(16)2024 Aug 10.
Article de Anglais | MEDLINE | ID: mdl-39204655

RÉSUMÉ

Buttonweed (Cotula coronopifolia) is native to South Africa but invasive in wetlands in Europe, North America, and Australasia, where it excludes native plants. Despite being dry-fruited, field studies suggest migratory waterbirds can disperse its seeds via gut passage (endozoochory), aiding its expansion. To explore the potential for endozoochory in different regions and habitats, we collected seeds from six populations in Spain, Sweden, and the UK. Germination was tested under different salinity levels (0, 5, 10, 15 g/L) and simulated gut passage treatments: scarification, acidification, or both. No germination occurred at 15 g/L. Higher salinity reduced and delayed germination, but full gut passage treatment (i.e., both scarification and acidification) increased germinability and accelerated germination. Scarification or acid treatment alone resulted in intermediate germination patterns. There were significant salinity × population and gut passage × population interactions on germinability. The acceleration effect of gut passage on germination was stronger at 5-10 g/L than at 0 g/L. This study highlights how migratory birds can facilitate the spread of alien plants introduced by humans. Endozoochory by waterbirds is an understudied mechanism for the long-distance dispersal of dry-fruited alien plants. Further research on C. coronopifolia, including population genetics, is necessary to understand dispersal mechanisms and facilitate management strategies.

4.
Nat Commun ; 15(1): 6790, 2024 Aug 08.
Article de Anglais | MEDLINE | ID: mdl-39117654

RÉSUMÉ

Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic features from a large cohort of ndDLBCL patients and identify seven clusters, one called A7 with poor prognosis, and develop a classifier to identify these clusters in independent ndDLBCL cohorts. This high-risk cluster is enriched for activated B-cell cell-of-origin, low immune infiltration, high MYC expression, and copy number aberrations. We compare and contrast our methodology with recent DLBCL classifiers to contextualize our clusters and show improved prognostic utility. Finally, using pre-clinical models, we demonstrate a mechanistic rationale for IKZF1/3 degraders such as lenalidomide to overcome the low immune infiltration phenotype of A7 by inducing T-cell trafficking into tumors and upregulating MHC I and II on tumor cells, and demonstrate that TCF4 is an important regulator of MYC-related biology in A7.


Sujet(s)
Régulation de l'expression des gènes tumoraux , Facteur de transcription Ikaros , Lénalidomide , Lymphome B diffus à grandes cellules , Protéines proto-oncogènes c-myc , Facteur-4 de transcription , Transcriptome , Lymphome B diffus à grandes cellules/génétique , Lymphome B diffus à grandes cellules/immunologie , Lymphome B diffus à grandes cellules/anatomopathologie , Humains , Protéines proto-oncogènes c-myc/génétique , Protéines proto-oncogènes c-myc/métabolisme , Lénalidomide/usage thérapeutique , Lénalidomide/pharmacologie , Facteur de transcription Ikaros/génétique , Facteur de transcription Ikaros/métabolisme , Facteur-4 de transcription/génétique , Facteur-4 de transcription/métabolisme , Lymphocytes B/métabolisme , Lymphocytes B/immunologie , Pronostic , Animaux , Lignée cellulaire tumorale , Analyse de profil d'expression de gènes/méthodes , Souris , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Variations de nombre de copies de segment d'ADN
5.
EClinicalMedicine ; 74: 102737, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39114271

RÉSUMÉ

Background: The Gender-Equity Model for liver Allocation corrected by serum sodium (GEMA-Na) and the Model for End-stage Liver Disease 3.0 (MELD 3.0) could amend sex disparities for accessing liver transplantation (LT). We aimed to assess these inequities in Spain and to compare the performance of GEMA-Na and MELD 3.0. Methods: Nationwide cohort study including adult patients listed for a first elective LT (January 2016-December 2021). The primary outcome was mortality or delisting for sickness within the first 90 days. Independent predictors of the primary outcome were evaluated using multivariate Cox's regression with adjusted relative risks (RR) and 95% confidence intervals (95% CI). The discrimination of GEMA-Na and MELD 3.0was assessed using Harrell c-statistics (Hc). Findings: The study included 6071 patients (4697 men and 1374 women). Mortality or delisting for clinical deterioration occurred in 286 patients at 90 days (4.7%). Women had reduced access to LT (83.7% vs. 85.9%; p = 0.037) and increased risk of mortality or delisting for sickness at 90 days (adjusted RR = 1.57 [95% CI 1.09-2.28]; p = 0.017). Female sex remained as an independent risk factor when using MELD or MELD-Na but lost its significance in the presence of GEMA-Na or MELD 3.0. Among patients included for reasons other than tumours (n = 3606; 59.4%), GEMA-Na had Hc = 0.753 (95% CI 0.715-0.792), which was higher than MELD 3.0 (Hc = 0.726 [95% CI 0.686-0.767; p = 0.001), showing both models adequate calibration. Interpretation: GEMA-Na and MELD 3.0 might correct sex disparities for accessing LT, but GEMA-Na provides more accurate predictions of waiting list outcomes and could be considered the standard of care for waiting list prioritization. Funding: Instituto de Salud Carlos III, Agencia Estatal de Investigación (Spain), and European Union.

6.
J Mater Chem B ; 12(31): 7618-7625, 2024 Aug 07.
Article de Anglais | MEDLINE | ID: mdl-38994651

RÉSUMÉ

The potential of using image-guided photodynamic therapy (ig-PDT) for cancer, especially with highly biocompatible fluorescent agents free of heavy atoms, is well recognized. This is due to key advantages related to minimizing adverse side effects associated with standard cancer chemotherapy. However, this theragnostic approach is strongly limited by the lack of synthetically-accessible and easily-modulable chemical scaffolds, enabling the rapid design and construction of advanced agents for clinical ig-PDT. In fact, there are still very few ig-PDT agents clinically approved. Herein we report a readily accessible, easy-tunable and highly fluorescent all-organic small photosensitizer, as a model design for accelerating the development and translation of advanced ig-PDT agents for cancer. This scaffold is based on BODIPY, which assures high fluorescence, accessibility, and ease of performance adaptation by workable chemistry. The optimal PDT performance of this BODIPY dye, tested in highly resistant pancreatic cancer cells, despite its high fluorescent behavior, maintained even after fixation and cancer cell death, is based on its selective accumulation in mitochondria. This induces apoptosis upon illumination, as evidenced by proteomic studies and flow cytometry. All these characteristics make the reported BODIPY-based fluorescent photosensitizer a valuable model for the rapid development of ig-PDT agents for clinical use.


Sujet(s)
Composés du bore , Colorants fluorescents , Photothérapie dynamique , Photosensibilisants , Photosensibilisants/composition chimique , Photosensibilisants/pharmacologie , Photosensibilisants/synthèse chimique , Humains , Composés du bore/composition chimique , Composés du bore/pharmacologie , Composés du bore/synthèse chimique , Colorants fluorescents/composition chimique , Colorants fluorescents/synthèse chimique , Colorants fluorescents/pharmacologie , Antinéoplasiques/composition chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/synthèse chimique , Structure moléculaire , Lignée cellulaire tumorale , Imagerie optique , Survie cellulaire/effets des médicaments et des substances chimiques
7.
J Biol Chem ; 300(8): 107557, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39002668

RÉSUMÉ

Glycosylphosphatidylinositol (GPI) anchor protein modification in Plasmodium species is well known and represents the principal form of glycosylation in these organisms. The structure and biosynthesis of GPI anchors of Plasmodium spp. has been primarily studied in the asexual blood stage of Plasmodium falciparum and is known to contain the typical conserved GPI structure of EtN-P-Man3GlcN-PI. Here, we have investigated the circumsporozoite protein (CSP) for the presence of a GPI anchor. CSP is the major surface protein of Plasmodium sporozoites, the infective stage of the malaria parasite. While it is widely assumed that CSP is a GPI-anchored cell surface protein, compelling biochemical evidence for this supposition is absent. Here, we employed metabolic labeling and mass-spectrometry-based approaches to confirm the presence of a GPI anchor in CSP. Biosynthetic radiolabeling of CSP with [3H]-palmitic acid and [3H]-ethanolamine, with the former being base-labile and therefore ester-linked, provided strong evidence for the presence of a GPI anchor on CSP, but these data alone were not definitive. To provide further evidence, immunoprecipitated CSP was analyzed for the presence of myo-inositol (a characteristic component of GPI anchor) using strong acid hydrolysis and GC-MS for highly sensitive and quantitative detection. The single ion monitoring (SIM) method for GC-MS analysis confirmed the presence of the myo-inositol component in CSP. Taken together, these data provide confidence that the long-assumed presence of a GPI anchor on this important parasite protein is correct.


Sujet(s)
Membrane cellulaire , Glycosylphosphatidylinositols , Plasmodium falciparum , Protéines de protozoaire , Sporozoïtes , Protéines de protozoaire/métabolisme , Glycosylphosphatidylinositols/métabolisme , Glycosylphosphatidylinositols/composition chimique , Membrane cellulaire/métabolisme , Sporozoïtes/métabolisme , Plasmodium falciparum/métabolisme , Animaux , Protéines membranaires/métabolisme , Humains
8.
Neuroscience ; 555: 125-133, 2024 Sep 13.
Article de Anglais | MEDLINE | ID: mdl-39038598

RÉSUMÉ

The role of adenosine receptors in fascial manipulation-induced analgesia has not yet been investigated. The purpose of this study was to evaluate the involvement of the adenosine A1 receptor (A1R) in the antihyperalgesic effect of plantar fascia manipulation (PFM), specifically in mice with peripheral inflammation. Mice injected with Complete Freund's Adjuvant (CFA) underwent behavioral, i.e. mechanical hyperalgesia and edema. The mice underwent PFM for either 3, 9 or 15 min. Response frequency to mechanical stimuli was then assessed at 24 and 96 h after plantar CFA injection. The adenosinergic receptors were assessed by systemic (intraperitoneal, i.p.), central (intrathecal, i.t.), and peripheral (intraplantar, i.pl.) administration of caffeine. The participation of the A1R was investigated using the 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a selective A1R subtype antagonist. PFM inhibited mechanical hyperalgesia induced by CFA injection and did not reduce paw edema. Furthermore, the antihyperalgesic effect of PFM was prevented by pretreatment of the animals with caffeine given by i.p., i.pl., and i.t. routes. In addition, i.pl. and i.t. administrations of DPCPX blocked the antihyperalgesia caused by PFM. These observations indicate that adenosine receptors mediate the antihyperalgesic effect of PFM. Caffeine's inhibition of PFM-induced antihyperalgesia suggests that a more precise understanding of how fascia-manipulation and caffeine interact is warranted.


Sujet(s)
Modèles animaux de maladie humaine , Adjuvant Freund , Hyperalgésie , Inflammation , Récepteur A1 à l'adénosine , Xanthines , Animaux , Récepteur A1 à l'adénosine/métabolisme , Récepteur A1 à l'adénosine/effets des médicaments et des substances chimiques , Souris , Mâle , Hyperalgésie/traitement médicamenteux , Hyperalgésie/métabolisme , Inflammation/métabolisme , Inflammation/traitement médicamenteux , Xanthines/pharmacologie , Fascia/effets des médicaments et des substances chimiques , Caféine/pharmacologie , Caféine/administration et posologie , Analgésie/méthodes , Moelle spinale/métabolisme , Moelle spinale/effets des médicaments et des substances chimiques , Antagonistes du récepteur A1 à l'adénosine/pharmacologie
9.
Blood Cancer J ; 14(1): 100, 2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38902256

RÉSUMÉ

Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an integrative multiomic approach to identify a signature at diagnosis that will identify DLBCL at high risk of early clinical failure. Tumor biopsies from 444 newly diagnosed DLBCL were analyzed by WES and RNAseq. A combination of weighted gene correlation network analysis and differential gene expression analysis was used to identify a signature associated with high risk of early clinical failure independent of IPI and COO. Further analysis revealed the signature was associated with metabolic reprogramming and identified cases with a depleted immune microenvironment. Finally, WES data was integrated into the signature and we found that inclusion of ARID1A mutations resulted in identification of 45% of cases with an early clinical failure which was validated in external DLBCL cohorts. This novel and integrative approach is the first to identify a signature at diagnosis, in a real-world cohort of DLBCL, that identifies patients at high risk for early clinical failure and may have significant implications for design of therapeutic options.


Sujet(s)
Lymphome B diffus à grandes cellules , Humains , Lymphome B diffus à grandes cellules/génétique , Lymphome B diffus à grandes cellules/diagnostic , Mâle , Femelle , Analyse de profil d'expression de gènes , Adulte d'âge moyen , Transcriptome , Mutation , Régulation de l'expression des gènes tumoraux , Facteurs de transcription/génétique , Marqueurs biologiques tumoraux/génétique , Sujet âgé , Pronostic , Microenvironnement tumoral , , Adulte , Protéines de liaison à l'ADN/génétique , Échec thérapeutique
10.
bioRxiv ; 2024 May 21.
Article de Anglais | MEDLINE | ID: mdl-38826328

RÉSUMÉ

Glycosylphosphatidylinositol (GPI) anchor protein modification in Plasmodium species is well known and represents the principal form of glycosylation in these organisms. The structure and biosynthesis of GPI anchors of Plasmodium spp. has been primarily studied in the asexual blood stage of P. falciparum and is known to contain the typical conserved GPI structure of EtN-P-Man3GlcN-PI. Here, we have investigated the circumsporozoite protein (CSP) for the presence of a GPI-anchor. CSP is the major surface protein of Plasmodium sporozoites, the infective stage of the malaria parasite. While it is widely assumed that CSP is a GPI-anchored cell surface protein, compelling biochemical evidence for this supposition is absent. Here, we employed metabolic labeling and mass-spectrometry based approaches to confirm the presence of a GPI anchor in CSP. Biosynthetic radiolabeling of CSP with [ 3 H]-palmitic acid and [ 3 H]-ethanolamine, with the former being base-labile and therefore ester-linked, provided strong evidence for the presence of a GPI anchor on CSP, but these data alone were not definitive. To provide further evidence, immunoprecipitated CSP was analyzed for presence of myo -inositol (a characteristic component of GPI anchor) using strong acid hydrolysis and GC-MS for a highly sensitive and quantitative detection. The single ion monitoring (SIM) method for GC-MS analysis confirmed the presence of the myo -inositol component in CSP. Taken together, these data provide confidence that the long-assumed presence of a GPI anchor on this important parasite protein is correct.

11.
FASEB J ; 38(11): e23726, 2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38847773

RÉSUMÉ

Calcitriol and calcimimetics are used to treat hyperparathyroidism secondary to chronic kidney disease (CKD). Calcitriol administration and the subsequent increase in serum calcium concentration decrease parathyroid hormone (PTH) levels, which should reduce bone remodeling. We have previously reported that, when maintaining a given concentration of PTH, the addition of calcimimetics is associated with an increased bone cell activity. Whether calcitriol administration affects bone cell activity while PTH is maintained constant should be evaluated in an animal model of renal osteodystrophy. The aim of the present study was to compare in CKD PTH-clamped rats the bone effects of calcitriol and calcimimetic administration. The results show that the administration of calcitriol and calcimimetic at doses that induced a similar reduction in PTH secretion produced dissimilar effects on osteoblast activity in 5/6 nephrectomized (Nx) rats with secondary hyperparathyroidism and in Nx rats with clamped PTH. Remarkably, in both rat models, the administration of calcitriol decreased osteoblastic activity, whereas calcimimetic increased bone cell activity. In vitro, calcitriol supplementation inhibited nuclear translocation of ß-catenin and reduced proliferation, osteogenesis, and mineralization in mesenchymal stem cells differentiated into osteoblasts. In conclusion, besides the action of calcitriol and calcimimetics at parathyroid level, these treatments have specific effects on bone cells that are independent of the PTH level.


Sujet(s)
Calcimimétiques , Calcitriol , Ostéoblastes , Hormone parathyroïdienne , Animaux , Calcitriol/pharmacologie , Rats , Calcimimétiques/pharmacologie , Calcimimétiques/usage thérapeutique , Hormone parathyroïdienne/pharmacologie , Mâle , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéoblastes/métabolisme , Hyperparathyroïdie secondaire/traitement médicamenteux , Hyperparathyroïdie secondaire/étiologie , Hyperparathyroïdie secondaire/métabolisme , Os et tissu osseux/métabolisme , Os et tissu osseux/effets des médicaments et des substances chimiques , Rat Wistar , Insuffisance rénale/traitement médicamenteux , Insuffisance rénale/métabolisme , Ostéogenèse/effets des médicaments et des substances chimiques , Insuffisance rénale chronique/traitement médicamenteux , Insuffisance rénale chronique/métabolisme , Insuffisance rénale chronique/complications , Différenciation cellulaire/effets des médicaments et des substances chimiques , Calcium/métabolisme
12.
Cell Rep Med ; 5(6): 101571, 2024 Jun 18.
Article de Anglais | MEDLINE | ID: mdl-38776914

RÉSUMÉ

Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled in CC-220-MM-001 (ClinicalTrials.gov: NCT02773030), a phase 1/2 study, shows that iberdomide treatment induces significant target substrate degradation in tumors, including in immunomodulatory agent (IMiD)-refractory patients or those with low CRBN levels. Additionally, some patients with CRBN genetic dysregulation who responded to iberdomide have a similar median progression-free survival (PFS) (10.9 months) and duration of response (DOR) (9.5 months) to those without CRBN dysregulation (11.2 month PFS, 9.4 month DOR). Iberdomide treatment promotes a cyclical pattern of immune stimulation without causing exhaustion, inducing a functional shift in T cells toward an activated/effector memory phenotype, including in triple-class refractory patients and those receiving IMiDs as a last line of therapy. This analysis demonstrates that iberdomide's clinical mechanisms of action are driven by both its cell-autonomous effects overcoming CRBN dysregulation in MM cells, and potent immune stimulation that augments anti-tumor immunity.


Sujet(s)
Myélome multiple , Thalidomide , Humains , Myélome multiple/traitement médicamenteux , Myélome multiple/immunologie , Myélome multiple/anatomopathologie , Myélome multiple/génétique , Thalidomide/usage thérapeutique , Thalidomide/pharmacologie , Protéines adaptatrices de la transduction du signal/métabolisme , Protéines adaptatrices de la transduction du signal/génétique , Ubiquitin-protein ligases/métabolisme , Ubiquitin-protein ligases/génétique , Femelle , Mâle , Récidive tumorale locale/anatomopathologie , Récidive tumorale locale/immunologie , Récidive tumorale locale/traitement médicamenteux , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Récidive , Adulte d'âge moyen , Lymphocytes T/immunologie , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/métabolisme , Sujet âgé
13.
J Public Health (Oxf) ; 46(3): e500-e509, 2024 Aug 25.
Article de Anglais | MEDLINE | ID: mdl-38704155

RÉSUMÉ

BACKGROUND: Urban farms are spaces designated for the cultivation of plants for food security, medicinal and curative purposes. Since the turn of the century, they have become more widespread and health benefits have been claimed; however, no consensus exists regarding this information. Hence, this study aims to provide information about the health effects of urban farming. METHODS: Protocol register number CRD42023448001. We followed the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Studies addressing urban farming interventions in any population group were included without age limitation of publication from PubMed, DOAJ, CAB Abstracts and NIH. Risk of bias was assessed using the Risk of Bias In Non-randomized Studies - of Interventions tool, and data were narratively synthesized. RESULTS: The search retrieved 2578 manuscripts, reduced to seven after screening. Urban farming's impact on health has been reflected in the physical domain by increasing self-reported health levels, physical activity, perceived general health, healthy eating and decreasing drug use. Parasites' presence has also been reported. In the mental aspect, urban farming is associated with relaxation and stress reduction. From a social perspective, urban farms provide a sense of belonging, personal growth and happiness. CONCLUSIONS: The benefits of urban farming outweigh the disadvantages. Further research should be conducted to clarify the potential benefits of this practice.


Sujet(s)
Agriculture , Humains , État de santé , Exercice physique , Population urbaine , Santé en zone urbaine , Santé mentale
14.
JMIR Mhealth Uhealth ; 12: e55483, 2024 May 16.
Article de Anglais | MEDLINE | ID: mdl-38754101

RÉSUMÉ

BACKGROUND: Depressive disorder and type 2 diabetes mellitus (T2DM) are prevalent in primary care (PC). Pharmacological treatment, despite controversy, is commonly chosen due to resource limitations and difficulties in accessing face-to-face interventions. Depression significantly impacts various aspects of a person's life, affecting adherence to medical prescriptions and glycemic control and leading to future complications and increased health care costs. To address these challenges, information and communication technologies (eg, eHealth) have been introduced, showing promise in improving treatment continuity and accessibility. However, while eHealth programs have demonstrated effectiveness in alleviating depressive symptoms, evidence regarding glycemic control remains inconclusive. This randomized controlled trial aimed to test the efficacy of a low-intensity psychological intervention via a web app for mild-moderate depressive symptoms in individuals with T2DM compared with treatment as usual (TAU) in PC. OBJECTIVE: This study aimed to analyze the cost-effectiveness and cost-utility of a web-based psychological intervention to treat depressive symptomatology in people with T2DM compared with TAU in a PC setting. METHODS: A multicenter randomized controlled trial was conducted with 49 patients with T2DM, depressive symptoms of moderate severity, and glycosylated hemoglobin (HbA1c) of 7.47% in PC settings. Patients were randomized to TAU (n=27) or a web-based psychological treatment group (n=22). This web-based treatment consisted of cognitive behavioral therapy, improvement of diabetes self-care behaviors, and mindfulness. Cost-effectiveness analysis for the improvement of depressive symptomatology was conducted based on reductions in 3, 5, or 50 points on the Patient Health Questionnaire-9 (PHQ-9). The efficacy of diabetes control was estimated based on a 0.5% reduction in HbA1c levels. Follow-up was performed at 3 and 6 months. The cost-utility analysis was performed based on quality-adjusted life years. RESULTS: Efficacy analysis showed that the web-based treatment program was more effective in improving depressive symptoms than TAU but showed only a slight improvement in HbA1c. Incremental cost-effectiveness ratios of 186.76 for a 3-point reduction in PHQ-9 and 206.31 for reductions of 5 and 50 percentage points were obtained. In contrast, the incremental cost-effectiveness ratio for improving HbA1c levels amounted to €1510.90 (€1=US $1.18 in 2018) per participant. The incremental cost-utility ratio resulted in €4119.33 per quality-adjusted life year gained. CONCLUSIONS: The intervention, using web-based modules incorporating cognitive behavioral therapy tools, diabetes self-care promotion, and mindfulness, effectively reduced depressive symptoms and enhanced glycemic control in patients with T2DM. Notably, it demonstrated clinical efficacy and economic efficiency. This supports the idea that eHealth interventions not only benefit patients clinically but also offer cost-effectiveness for health care systems. The study emphasizes the importance of including specific modules to enhance diabetes self-care behaviors in future web-based psychological interventions, emphasizing personalization and adaptation for this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT03426709; https://clinicaltrials.gov/study/NCT03426709. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1186/S12888-019-2037-3.


Sujet(s)
Analyse coût-bénéfice , Dépression , Diabète de type 2 , Soins de santé primaires , Humains , Diabète de type 2/thérapie , Diabète de type 2/psychologie , Diabète de type 2/complications , Mâle , Femelle , Soins de santé primaires/statistiques et données numériques , Soins de santé primaires/économie , Adulte d'âge moyen , Analyse coût-bénéfice/statistiques et données numériques , Dépression/thérapie , Dépression/psychologie , Sujet âgé , Internet , Adulte , Résultat thérapeutique
15.
J Clin Pediatr Dent ; 48(3): 146-155, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38755993

RÉSUMÉ

The objective of this work was to estimate the prevalence and severity of erosive tooth wear (ETW), and to identify risk indicators of deciduous dentition of a group of schoolchildren from public schools in Tlalnepantla de Baz, State of Mexico. A cross-sectional study was carried out in 352 schoolchildren from 5 to 7 years old. The severity of the ETW was evaluated using the Basic Erosive Wear Examination (BEWE). Risk indicators were evaluated through a survey which included food and beverage consumption, consumption habits, vitamin C consumption, gastroesophageal reflux, heartburn, belching, xerostomia, vomiting and teeth grinding. Multinomial logistic regression models were fitted. The prevalence of ETW was 99.7% (n = 351). Regarding severity, 46.6% were at a null/mild level, 27.3% moderate, and 26.1% severe. Males were more likely to present severe ETW (odds ratio (OR) = 2.23, 95% confidence interval (CI), 1.27-3.93; p = 0.005). The risk indicators for the severity of ETW were the frequent consumption of citrus fruits (OR = 2.09, 95% CI, 1.12-3.89; p = 0.021), fruit juice (OR = 1.99, 95% CI, 1.06-3.75; p = 0.033), processed beverages (OR = 2.15, 95% CI, 1.23-3.78; p = 0.008) and hot sauce (OR = 1.82, 95% CI, 1.03-3.20; p = 0.036). The prevalence of ETW in the deciduous dentition was very high (99.7%) and ~1/3 for severe ETW. The dietary factors associated with severe ETW are part of the regular consumption of Mexican school-age children, which impact their oral health condition. It is important to establish intervention strategies from the infant stage, focused on both children and their caregivers.


Sujet(s)
Érosion dentaire , Dent de lait , Humains , Dent de lait/anatomopathologie , Mexique/épidémiologie , Mâle , Érosion dentaire/épidémiologie , Études transversales , Femelle , Enfant d'âge préscolaire , Enfant , Facteurs de risque , Prévalence , Indice de gravité de la maladie , Comportement alimentaire , Acide ascorbique , Reflux gastro-oesophagien/épidémiologie , Citrus , Régime alimentaire , Boissons
16.
Antiviral Res ; 227: 105918, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38795911

RÉSUMÉ

The most widely used class of antivirals available for Influenza treatment are the neuraminidase inhibitors (NAI) Oseltamivir and Zanamivir. However, amino acid (AA) substitutions in the neuraminidase may cause reduced inhibition or high antiviral resistance. In Mexico, the current state of knowledge about NAI susceptibility is scarce, in this study we report the results of 14 years of Influenza surveillance by phenotypic and genotypic methods. A total of 255 isolates were assessed with the NAI assay, including Influenza A(H1N1)pdm09, A(H3N2) and Influenza B (IBV). Furthermore, 827 sequences contained in the GISAID platform were analyzed in search of relevant mutations.Overall, five isolates showed highly reduced inhibition or reduced inhibition to Oseltamivir, and two showed reduced inhibition to Zanamivir in the NAI assays. Additionally, five A(H1N1)pdm09 sequences from the GISAID possessed AA substitutions associated to reduced inhibition to Oseltamivir and none to Zanamivir. Oseltamivir resistant A(H1N1)pdm09 harbored the H275Y mutation. No genetic mutations were identified in Influenza A(H3N2) and IBV. Overall, these results show that in Mexico the rate of NAI resistance is low (0.6%), but it is essential to continue the Influenza surveillance in order to understand the drug susceptibility of circulating strains.


Sujet(s)
Antiviraux , Résistance virale aux médicaments , Virus influenza B , Grippe humaine , Sialidase , Oséltamivir , Zanamivir , Résistance virale aux médicaments/génétique , Antiviraux/pharmacologie , Mexique/épidémiologie , Humains , Virus influenza B/effets des médicaments et des substances chimiques , Virus influenza B/génétique , Grippe humaine/virologie , Grippe humaine/traitement médicamenteux , Grippe humaine/épidémiologie , Oséltamivir/pharmacologie , Zanamivir/pharmacologie , Sialidase/génétique , Sialidase/antagonistes et inhibiteurs , Sous-type H1N1 du virus de la grippe A/effets des médicaments et des substances chimiques , Sous-type H1N1 du virus de la grippe A/génétique , Sous-type H1N1 du virus de la grippe A/isolement et purification , Mutation , Sous-type H3N2 du virus de la grippe A/effets des médicaments et des substances chimiques , Sous-type H3N2 du virus de la grippe A/génétique , Adulte , Virus de la grippe A/effets des médicaments et des substances chimiques , Virus de la grippe A/génétique , Adolescent , Enfant , Substitution d'acide aminé , Jeune adulte , Adulte d'âge moyen , Femelle , Enfant d'âge préscolaire , Génotype , Mâle , Sujet âgé , Tests de sensibilité microbienne , Protéines virales/génétique
17.
Hepatol Commun ; 8(5)2024 May 01.
Article de Anglais | MEDLINE | ID: mdl-38701490

RÉSUMÉ

BACKGROUND: Frailty is a predictive factor of hospitalization, falls, and mortality in patients with cirrhosis, regardless of the degree of liver failure. The aim was to analyze whether a multifactorial intervention consisting of home-based exercise, branched-chain amino acids, and a multistrain probiotic can improve frailty in these patients. METHODS: Outpatients with cirrhosis were classified according to the Liver Frailty Index (LFI). Prefrail and frail patients were randomized into 2 groups. The intervention group was assigned to a multifactorial intervention consisting of exercise at home, branched-chain amino acid supplements, and a multistrain probiotic for 12 months. The control group received standard care. All patients were prospectively followed up every 3 months for 1 year to determine LFI, incidence of falls, emergency room visits, hospitalizations, and mortality. RESULTS: Thirty-two patients were included: 17 patients were assigned to the intervention group and 15 to the control group. In the intervention group, the baseline LFI decreased at 3, 6, 9, and 12 months (p = 0.019 for overall change with respect to the control group). The change in LFI (ΔLFI) at 12 months was -0.71 ± 0.24 in the intervention group and -0.09 ± 0.32 in the control group (p<0.001). During follow-up, patients in the intervention group had a lower 1-year probability of falls (6% vs. 47%, p = 0.03) and emergency room visits (10% vs. 44%, p = 0.04) than patients in the control group. CONCLUSIONS: A long-term multifactorial intervention that included exercise at home, branched-chain amino acids, and a multistrain probiotic improved frailty in outpatients with cirrhosis and was associated with a decrease in the incidence of clinical events such as falls and emergency room visits.


Sujet(s)
Acides aminés à chaine ramifiée , Fragilité , Cirrhose du foie , Probiotiques , Humains , Mâle , Femelle , Cirrhose du foie/complications , Acides aminés à chaine ramifiée/usage thérapeutique , Acides aminés à chaine ramifiée/administration et posologie , Probiotiques/usage thérapeutique , Adulte d'âge moyen , Sujet âgé , Hospitalisation/statistiques et données numériques , Chutes accidentelles/prévention et contrôle , Traitement par les exercices physiques , Études prospectives , Résultat thérapeutique , Compléments alimentaires
18.
Mov Disord ; 39(6): 1065-1070, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38610104

RÉSUMÉ

BACKGROUND: The GPNMB single-nucleotide polymorphism rs199347 and GBA1 variants both associate with Lewy body disorder (LBD) risk. GPNMB encodes glycoprotein nonmetastatic melanoma protein B (GPNMB), a biomarker for GBA1-associated Gaucher's disease. OBJECTIVE: The aim of this study was to determine whether GPNMB levels (1) differ in LBD with and without GBA1 variants and (2) associate with rs199347 genotype. METHODS: We quantified GPNMB levels in plasma and cerebrospinal fluid (CSF) from 124 individuals with LBD with one GBA1 variant (121 plasma, 14 CSF), 631 individuals with LBD without GBA1 variants (626 plasma, 41 CSF), 9 neurologically normal individuals with one GBA1 variant (plasma), and 2 individuals with two GBA1 variants (plasma). We tested for associations between GPNMB levels and rs199347 or GBA1 status. RESULTS: GPNMB levels associate with rs199347 genotype in plasma (P = 0.022) and CSF (P = 0.007), but not with GBA1 status. CONCLUSIONS: rs199347 is a protein quantitative trait locus for GPNMB. GPNMB levels are unaltered in individuals carrying one GBA1 variant. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


Sujet(s)
Marqueurs biologiques , Glucosylceramidase , Maladie à corps de Lewy , Glycoprotéines membranaires , Polymorphisme de nucléotide simple , Humains , Femelle , Glucosylceramidase/génétique , Mâle , Maladie à corps de Lewy/génétique , Maladie à corps de Lewy/liquide cérébrospinal , Maladie à corps de Lewy/sang , Glycoprotéines membranaires/génétique , Glycoprotéines membranaires/liquide cérébrospinal , Sujet âgé , Adulte d'âge moyen , Marqueurs biologiques/sang , Marqueurs biologiques/liquide cérébrospinal , Sujet âgé de 80 ans ou plus , Génotype , Hétérozygote , Maladie de Gaucher/génétique , Maladie de Gaucher/sang , Maladie de Gaucher/liquide cérébrospinal
19.
Clin Microbiol Infect ; 30(8): 1035-1041, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38599464

RÉSUMÉ

OBJECTIVES: This study aimed to determine the association of Escherichia coli microbiological factors with 30-day mortality in patients with bloodstream infection (BSI) presenting with a dysregulated response to infection (i.e. sepsis or septic shock). METHODS: Whole-genome sequencing was performed on 224 E coli isolates of patients with sepsis/septic shock, from 22 Spanish hospitals. Phylogroup, sequence type, virulence, antibiotic resistance, and pathogenicity islands were assessed. A multivariable model for 30-day mortality including clinical and epidemiological variables was built, to which microbiological variables were hierarchically added. The predictive capacity of the models was estimated by the area under the receiver operating characteristic curve (AUROC) with 95% confidence intervals (CI). RESULTS: Mortality at day 30 was 31% (69 patients). The clinical model for mortality included (adjusted OR; 95% CI) age (1.04; 1.02-1.07), Charlson index ≥3 (1.78; 0.95-3.32), urinary BSI source (0.30; 0.16-0.57), and active empirical treatment (0.36; 0.11-1.14) with an AUROC of 0.73 (95% CI, 0.67-0.80). Addition of microbiological factors selected clone ST95 (3.64; 0.94-14.04), eilA gene (2.62; 1.14-6.02), and astA gene (2.39; 0.87-6.59) as associated with mortality, with an AUROC of 0.76 (0.69-0.82). DISCUSSION: Despite having a modest overall contribution, some microbiological factors were associated with increased odds of death and deserve to be studied as potential therapeutic or preventive targets.


Sujet(s)
Bactériémie , Infections à Escherichia coli , Escherichia coli , Choc septique , Humains , Infections à Escherichia coli/microbiologie , Infections à Escherichia coli/mortalité , Mâle , Études prospectives , Sujet âgé , Femelle , Bactériémie/microbiologie , Bactériémie/mortalité , Escherichia coli/génétique , Escherichia coli/isolement et purification , Escherichia coli/pathogénicité , Escherichia coli/classification , Choc septique/microbiologie , Choc septique/mortalité , Adulte d'âge moyen , Sujet âgé de 80 ans ou plus , Espagne/épidémiologie , Séquençage du génome entier , Sepsie/microbiologie , Sepsie/mortalité , Courbe ROC , Antibactériens/usage thérapeutique , Antibactériens/pharmacologie , Virulence , Facteurs de virulence/génétique
20.
Int J Mol Sci ; 25(8)2024 Apr 10.
Article de Anglais | MEDLINE | ID: mdl-38673780

RÉSUMÉ

Cognitive impairment (CI) is a complication of chronic kidney disease (CKD) that is frequently observed among patients. The aim of this study was to evaluate the potential crosstalk between changes in cognitive function and the levels of Klotho in the brain cortex in an experimental model of CKD. To induce renal damage, Wistar rats received a diet containing 0.25% adenine for six weeks, while the control group was fed a standard diet. The animals underwent different tests for the assessment of cognitive function. At sacrifice, changes in the parameters of mineral metabolism and the expression of Klotho in the kidney and frontal cortex were evaluated. The animals with CKD exhibited impaired behavior in the cognitive tests in comparison with the rats with normal renal function. At sacrifice, CKD-associated mineral disorder was confirmed by the presence of the expected disturbances in the plasma phosphorus, PTH, and both intact and c-terminal FGF23, along with a reduced abundance of renal Klotho. Interestingly, a marked and significant decrease in Klotho was observed in the cerebral cortex of the animals with renal dysfunction. In sum, the loss in cerebral Klotho observed in experimental CKD may contribute to the cognitive dysfunction frequently observed among patients. Although further studies are required, Klotho might have a relevant role in the development of CKD-associated CI and represent a potential target in the management of this complication.


Sujet(s)
Cortex cérébral , Dysfonctionnement cognitif , Glucuronidase , Protéines Klotho , Insuffisance rénale chronique , Animaux , Mâle , Rats , Cortex cérébral/métabolisme , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/étiologie , Modèles animaux de maladie humaine , Facteur-23 de croissance des fibroblastes/métabolisme , Facteurs de croissance fibroblastique/métabolisme , Glucuronidase/métabolisme , Rein/métabolisme , Protéines Klotho/métabolisme , Rat Wistar , Insuffisance rénale chronique/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE